Genedx Holdings Corp. (WGS) Stock Price & Analysis
Genedx Holdings Corp. (WGS) rose 8.75% to USD 56.33 as of June 10, 2026 at 05:10 UTC, according to Nexqual real-time market data.
WGS last closed at USD 51.8; the session ranged USD 52.28–57.08 on volume of 1,377,595 shares. Market capitalization is $1.67B, with a 52-week range of USD 32.21–170.87 (NMS). Source: Nexqual, June 10, 2026 at 05:10 UTC.
Key Statistics (as of June 10, 2026 at 05:10 UTC)
| Price | USD 56.33 |
|---|---|
| Change | ▲ 8.75% (up) |
| Previous Close | USD 51.8 |
| Open | USD 53.79 |
| Day Range | USD 52.28 – 57.08 |
| 52-Week Range | USD 32.21 – 170.87 |
| Volume | 1,377,595 shares |
| Market Cap | $1.67B |
| Exchange | NMS |
Technical Analysis (WGS)
Nexqual's technical model rates WGS "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 05:10 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.13 (neutral) |
| vs SMA50 | Above (USD 55.65) |
| MACD | -0.36 (negative) |
Analyst Ratings (WGS)
Wall Street analysts rate WGS "Strong Buy" based on 9 analysts, with a mean price target of USD 77 (range USD 50–100), per Nexqual as of June 10, 2026 at 05:10 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 77 |
| High Target | USD 100 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (WGS)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $111.01M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.28 vs est -0.02 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.12 ▲ beat |
| 2025-09-30 | USD 0.49 vs est 0.42 ▲ beat |
| 2025-06-30 | USD 0.5 vs est 0.11 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:10 UTC.
Financials & Fundamentals (WGS)
| Total Revenue | $442.68M |
|---|---|
| Revenue Growth (YoY) | +17.40% |
| Gross Margin | +69.56% |
| Operating Margin | -25.61% |
| Profit Margin | -17.58% |
| ROE | -30.42% |
| Debt / Equity | 66.19 |
| Current Ratio | 3.09 |
| Total Cash | $170.68M |
| Total Debt | $168.19M |
| Free Cash Flow | $3.64M |
Source: Nexqual, June 10, 2026 at 05:10 UTC.
Financial Health Score (WGS)
Nexqual rates Genedx Holdings Corp.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:10 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 70%, operating -26% |
| Balance Sheet | Strong — $171M cash vs $168M debt, net cash position |
| Cash Flow | Mixed — FCF $4M, slim 0.9% margin |
| Efficiency | Critical — ROE -30%, ROA -4.4% |
Ownership (WGS)
| Insider Ownership | +12.12% |
|---|---|
| Institutional Ownership | +112.80% |
| Shares Outstanding | 29.69M |
| Float | 18.81M |
| Short % of Float | +29.60% |
Source: Nexqual, June 10, 2026 at 05:10 UTC.
Leadership (WGS)
Genedx Holdings Corp. is led by Katherine A. Stueland (age 49), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:10 UTC.
| President, CEO & Director | Katherine A. Stueland (age 49) |
|---|---|
| Chief Financial Officer | Kevin Feeley (age 44) |
| Chief Operating Officer | Bryan M. Dechairo (age 52) |
| Director of Investor Relations & Communications | Sabrina V. Dunbar |
Major Backers & Investors (WGS)
Notable institutional backers of Genedx Holdings Corp. include Corvex Management LP, Casdin Capital, LLC, ARK Invest, according to Nexqual as of June 10, 2026 at 05:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Corvex Management LP | 10.87% |
| Casdin Capital, LLC | 10.13% |
| ARK Invest | 9.46% |
| Westfield Capital Management Co LP | 4.61% |
| Goldman Sachs | 4.5% |
| Oracle Investment Management Inc | 2.98% |
| William Blair Investment Management, LLC | 2.61% |
| Zweig-Dimenna Associates LLC | 2.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.73% |
| Vanguard Group | 4.91% |
Source: Nexqual, June 10, 2026 at 05:10 UTC.
From Genedx Holdings Corp.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses.
- To achieve these objectives, we: • Deploy our team of approximately 120 field-based sales representatives and medical science liaisons, and construct an industry-leading brand, product, marketing, communications and market access platform that leverages our expertise, rich data, and decades of earned trust across the genetics community. • Partner with leaders across health systems, manufacturers, commercial and governmental payors and advocacy groups.
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, these steps may be circumvented, or third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- We are also applying AI tools – like our machine learning powered gene ranker, Multiscore – on top of GeneDx Infinity TM to harness the power of our data, scale our platform and increase speed and turnaround time.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SEZL | Sezzle Inc. | USD 121.5 | ▲ 4.73% |
| NTRA | Natera, Inc. | USD 222.82 | ▲ 3.49% |
| GRAL | GRAIL, Inc. | USD 60.9 | ▲ 1.53% |
| SMMT | Summit Therapeutics Inc. | USD 14.29 | ▼ 3.25% |
| JANX | Janux Therapeutics, Inc. | USD 13.62 | ▲ 1.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:10 UTC. This page is informational and not investment advice.